Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Bolt Biotherapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. The busiest examiner, METCALF, MATTHEW CURRAN, is responsible for 1 pending action. This indicates that the 2 pending actions are being handled by different examiners in different parts of the office. With 2 pending actions, the company is navigating multiple review channels within the biotechnology field.
The presence of 2 distinct examiners and 2 distinct art units suggests a diversified prosecution strategy. Because the workload is split, the company can compare the feedback from different parts of the office to refine its overall approach to Biotechnology & Pharmaceuticals. Success for Bolt Biotherapeutics Inc. depends on navigating the specific requirements of both METCALF, MATTHEW CURRAN and the other assigned examiner. This distribution reduces the impact of any single examiner's tendencies on the entire portfolio.
In the biotechnology sector, having multiple art units involved can indicate that the patent applications cover different technical aspects of the field. Practitioners should monitor the historical allowance rates for each distinct art unit to anticipate potential challenges. With 2 pending office actions, the company has the opportunity to build a broader patent base by successfully managing the distinct perspectives of the 2 distinct examiners involved in the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017541 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | DAHLIN, HEATHER RAQUEL | 2d overdue |
| 18283071 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | METCALF, MATTHEW CURRAN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283071 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18017541 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | §112 | Final Rejection | 2d overdue | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial